| Literature DB >> 27334052 |
Ravinder Kang1, Philip P Goodney1, Sandra L Wong1.
Abstract
The cost of cancer care has increased by five fold over the last three decades. As our healthcare system shifts from volume to value, greater scrutiny of interventions with clinical equipoise is required. Traditionally, QALYs and ICER have served as surrogate markers for value. However, this approach fails to incorporate all stakeholders' viewpoints. Prostate cancer, low risk DCIS, and thyroid cancer are used as a framework to discuss value and cost-effectiveness. J. Surg. Oncol. 2016;114:275-280.Entities:
Keywords: ICER; QALY; ductal carcinoma in-situ; prostate cancer; thyroid cancer; value
Mesh:
Year: 2016 PMID: 27334052 PMCID: PMC5048466 DOI: 10.1002/jso.24331
Source DB: PubMed Journal: J Surg Oncol ISSN: 0022-4790 Impact factor: 3.454